Nuclear receptor ligands and ligand binding domains

Details Nuclear receptor ligands and ligand binding domains Nuclear receptor ligands and ligand binding domains

1996-12-13

2001-05-22

Eyler, Yvonne (Department: 1646)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Chemical analysis

C702S019000, C702S020000, C530S350000

Reexamination Certificate

active

06236946

ABSTRACT:

INTRODUCTION
1. Technical Field
This invention relates to computational methods for designing ligands that bind to nuclear receptors, crystals of nuclear receptors, synthetic ligands of nuclear receptors and methods of using synthetic ligands.
2. Background
Nuclear receptors represent a superfamily of proteins that specifically bind a physiologically relevant small molecule, such as hormone or vitamin. As a result of a molecule binding to a nuclear receptor, the nuclear receptor changes the ability of a cell to transcribe DNA, i.e. nuclear receptors modulate the transcription of DNA, although they may have transcription independent actions. Unlike integral membrane receptors and membrane associated receptors, the nuclear receptors reside in either the cytoplasm or nucleus of eukaryotic cells. Thus, nuclear receptors comprise a class of intracellular, soluble ligand-regulated transcription factors.
Nuclear receptors include receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), vitamin D (VDRs), retinoids (RARs and RXRs). The so called “orphan receptors” are also part of the nuclear receptor superfamily, as they are structurally homologous to the classic nuclear receptors, such as steroid and thyroid receptors. To date, ligands have not been identified with orphan receptors but it is likely that small molecule ligands will be discovered in the near future for this class of transcription factors. Generally, nuclear receptors specifically bind physiologically relevant small molecules with high affinity and apparent Kd's are commonly in the 0.01-20 nM range, depending on the nuclear receptor/ligand pair.
Development of synthetic ligands that specifically bind to nuclear receptors has been largely guided by the trial and error method of drug design despite the importance of nuclear receptors in a myriad of physiological processes and medical conditions such as hypertension, inflammation, hormone dependent cancers (e.g. breast and prostate cancer), modulation of reproductive organ modulation, hyperthyroidism, hypercholesterolemia and obesity. Previously, new ligands specific for nuclear receptors were discovered in the absence of information on the three dimensional structure of a nuclear receptor with a bound ligand. Before the present invention, researchers were essentially discovering nuclear receptor ligands by probing in the dark and without the ability to visualize how the amino acids of a nuclear receptor held a ligand in its grasp.
Consequently, it would be advantageous to devise methods and compositions for reducing the time required to discover ligands to nuclear receptors, synthesize such compounds and administer such compounds to organisms to modulate physiological processes regulated by nuclear receptors.
SUMMARY OF THE INVENTION
The present invention provides for crystals of nuclear receptor ligand binding domains with a ligand bound to the ligand binding domain (LBD). The crystals of the present invention provide excellent atomic resolution of the amino acids that interact with nuclear receptor ligand, especially thyroid receptor ligands. The three dimensional model of a nuclear receptor LBD with a ligand bound reveals a previously unknown structure for nuclear receptors and shows that the ligand is bound in a water inaccessible binding cavity of the ligand binding domain of the nuclear receptor.
The present invention also provides for computational methods using three dimensional models of nuclear receptors that are based on crystals of nuclear receptor LBDs. Generally, the computational method of designing a nuclear receptor ligand determines which amino acid or amino acids of a nuclear receptor LBD interact with a chemical moiety (at least one) of the ligand using a three dimensional model of a crystallized protein comprising a nuclear receptor LBD with a bound ligand, and selecting a chemical modification (at least one) of the chemical moiety to produce a second chemical moiety with a structure that either decreases or increases an interaction between the interacting amino acid and the second chemical moiety compared to the interaction between the interacting amino acid and the corresponding chemical moiety on the natural hormone.


REFERENCES:
patent: 4741897 (1988-05-01), Andrews et al.
patent: 4766121 (1988-08-01), Ellis et al.
patent: 4826876 (1989-05-01), Ellis et al.
patent: 4910305 (1990-03-01), Ellis et al.
patent: 5061798 (1991-10-01), Emmett et al.
patent: 5116828 (1992-05-01), Miura et al.
patent: 5171671 (1992-12-01), Evans et al.
patent: 5284999 (1994-02-01), Chin et al.
patent: 5312732 (1994-05-01), Evans
patent: 5322933 (1994-06-01), Davies et al.
patent: 5403925 (1995-04-01), Ozato
patent: 5438126 (1995-08-01), DeGroot et al.
patent: 5466861 (1995-11-01), Dawson et al.
patent: WO 97/21993 (1997-06-01), None
patent: WO 98/07435 (1998-02-01), None
patent: WO 98/57919 (1998-12-01), None
Andrea, T.A., et al., “A Model for Thyroid Hormone-Receptor Interactions”,J. Med. Chem.,vol.22:221-232 (1979).
Apriletti, J.W., et al., “Expression of the Rat &agr;1 Thyroid Hormone Receptor Ligand Binding Domain inEscherichia coliand the Use of a Ligand-Induced Conformation Change as a Method for its Purification to Homogeneity”,Protein Expression and Purification,vol.6:363-370 (1995).
Apriletti, J.W., et al., “Large Scale Purification of the Nuclear Thyroid Hormone Receptor From Rat Liver and Sequence-specific Binding of the Receptor to DNA”,J. Biol. Chem.,vol.263:9409-9417 (1988).
Au-Fliegner, et al., “The Conserved Ninth C-Terminal Heptad in Thyroid Hormone and Retinoic Acid Receptors Mediates Diverse Responses by Affecting Heterodimer but Not Homodimer Formation”,Mol.Cell Biol.,vol.13:5725-5737 (1993).
Baniahmad, A., et al.“The &tgr;4 Activation Domain of the Thyroid Hormone Receptor is Required for Release of a Putative Corepressor(s) Necessary for Transcriptional Silencing”,Mol.Cell Biol.,vol. 15,:76-86 (1995).
Barettino, D., et al., “Characterization of the Ligand-dependent Transactivation Domain of Thyroid Hormone Receptor”,Embo.J.,vol.13:3039-3049 (1994).
Barker, et al.,“Thyroxine Antagonism by Partially Iodinated Thyronines and Analogues”,Ann.N.Y.Acad.Sci.,vol. 86:545-562 (1960).
Beck-Peccoz, P., et al., “Nomenclature of Thyroid Hormone Receptor &bgr;-Gene Mutations in Resistance to Thyroid Hormone: Consensus Statement from the First Workshop on Thyroid Hormone Resistance, Jul. 10-11, 1993 Cambridge, United Kingdom”,J.Clin.Endocrinol Metab.,vol. 78:990-993 (1994).
Bhat, M.K., et al., “Interaction of Thyroid Hormone Nuclear Receptor With Antibody: Characterization of the Thyroid Hormone Binding Site”,Biochem.Biophys.Res.Commun.,vol.210:464-471 (1995).
Blake, C.C. & Oatley, S.J., “Protein-DNA and Protein-Hormone Interactions in prealbumin: a Model of the Thyroid Hormone Nuclear Receptor?”,Nature,vol.268:115-120 (1977).
Blake, C.C., et al., “Structure of Prealbumin: Secondary, Tertiary and Quarternary Interactions Determined by Fourier Refinement at 1 8 A”,J.Mol.Biol.,vol.121:339-356 (1978).
Bourguet, W., et al., “Crystal Structure of the Ligand-Binding Domain of the Human Nuclear Receptor RXR-&agr;”,Nature,vol.375:377-382 (1995).
Brent, G.A., “The Moledular Basis of Thyroid Hormone Action”,N.Engl.J.Med.,vol.331:847-853 (1994).
Brunger, A.T., et al., “Crystallographic R Factor Refinement by Molecular Dynamics”,Science,vol.235:458-460 (1987).
Casanova, J., et al., “Functional Evidence for Ligand-Dependent Dissociation of Thyroid Hormone and Retinoic Acid Receptors from an Inhibitory Cellular Factor”,Mol.Cell.Biol.,vol.14:5756-5765 (1994).
Cavailles, V. et al., “Nuclear Factor RIP140 Modulates Transcriptional Activation by the Estrogen Receptor”,Embo, J.,vol.14:3741-3751 (1995).
Collaborative Computational Project, N. 4., “The CCP4 Suite: Programs for Protein Crystallography”,Acta Crystallogr.,vol.D50:760-763 (1994).
Collingwood, T.N., et al., “Spectrum of Transcriptional, Dimerization, and Dominant Negative Properties of Twenty Different Mutant Thyroid Hormone &bgr;-R

Affiliated with

Also associated with

Rating

Nuclear receptor ligands and ligand binding domains does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nuclear receptor ligands and ligand binding domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclear receptor ligands and ligand binding domains will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2544965